{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:27:35Z","timestamp":1791660455515,"version":"4.3.4"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.athplu.2026.100569","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:38:14Z","timestamp":1778168294000},"page":"100569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances"],"prefix":"10.1016","volume":"65","author":[{"given":"Wael","family":"Almahmeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-1056","authenticated-orcid":false,"given":"Hani","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronney","family":"Shantouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Aljaberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"El Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Bin Lootah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Al Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwairia","family":"AlAli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousa","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"AlSarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al Waili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2026.100569_bib1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.athplu.2026.100569_bib4","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranh\u00e3o","year":"2014","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.123.066398","article-title":"Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests","volume":"149","author":"Szarek","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib6","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100569_bib7","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.3390\/jcm11206040","article-title":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies","volume":"11","author":"Bhatia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2026.100569_bib8","first-page":"397","article-title":"Lipoprotein(a) is a prevalent yet vastly underrecognized risk factor for cardiovascular disease","volume":"12","author":"Rendler","year":"2024","journal-title":"Health Care Curr Rev"},{"key":"10.1016\/j.athplu.2026.100569_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1194\/jlr.E066985","article-title":"Lipoprotein (a): coming of Age at last","volume":"57","author":"Witztum","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein.(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2026.100569_bib11","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000001429","article-title":"Potential novel RNA-Targeting agents for effective Lipoprotein(a) lowering: a systematic assessment of the evidence from completed and ongoing developmental clinical trials","volume":"82","author":"Milosavljevic","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.athplu.2026.100569_bib13","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.3390\/jcm11133884","article-title":"Antisense oligonucleotides and small interfering RNA for the treatment of Dyslipidemias","volume":"11","author":"Gareri","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2026.100569_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290286","article-title":"The burden of ischemic heart disease and the epidemiologic transition in the Eastern Mediterranean Region: 1990\u20132019","volume":"18","author":"Sadeghi","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2026.100569_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2016.09.081","article-title":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East","volume":"225","author":"Al Sayed","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102341","article-title":"Cardiovascular disease burden in the Middle East and North Africa region","volume":"49","author":"Alhuneafat","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-2275(20)38724-1","article-title":"Isolation and characterization of the two major apoproteins in human lipoprotein [a]","volume":"28","author":"Gaubatz","year":"1986","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.athplu.2026.100569_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0022-2275(20)42790-7","article-title":"Solubility, immunochemical, and lipoprotein binding properties of apoB-100-apo[a], the protein moiety of lipoprotein[a]","volume":"31","author":"Fless","year":"1990","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","article-title":"Apo(a) and ApoB interact noncovalently within hepatocytes: implications for regulation of lp(a) levels by modulation of ApoB secretion","volume":"42","author":"Youssef","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100569_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Ors\u00f3","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.athplu.2026.100569_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/clc.4960270503","article-title":"Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis","volume":"27","author":"Deb","year":"2004","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib23","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.athplu.2026.100569_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.atherosclerosis.2023.02.007","article-title":"Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: a survey among the Lipid Clinics Network","volume":"370","author":"Catapano","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.athplu.2026.100569_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new Insight into the structure, function, metabolism, pathogenicity, and medications affecting Lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"key":"10.1016\/j.athplu.2026.100569_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00001721-199112000-00010","article-title":"Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner","volume":"2","author":"Edelberg","year":"1991","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.athplu.2026.100569_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2298\/MPNS0702037V","article-title":"[Lipoprotein(a): a link between thrombogenesis and atherogenesis]","volume":"60","author":"Vuckovi\u0107","year":"2007","journal-title":"Med Pregl"},{"key":"10.1016\/j.athplu.2026.100569_bib32","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.numecd.2023.07.019","article-title":"Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)","volume":"33","author":"Chiesa","year":"2023","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2026.100569_bib33","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a) an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100569_bib34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the national heart, lung, and Blood Institute workshop on Lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2026.100569_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016604","article-title":"Variation in LPA is associated with lp(a) levels in three populations from the third National Health and Nutrition Examination Survey","volume":"6","author":"Dumitrescu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2026.100569_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Investig"},{"key":"10.1016\/j.athplu.2026.100569_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12944-018-0753-1","article-title":"Low LPA gene kringle IV-2 repeat copy number association with elevated lipoprotein (a) concentration as an independent risk factor of coronary atherosclerotic heart disease in the Chinese Han population","volume":"17","author":"Sun","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.athplu.2026.100569_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12920-024-02024-0","article-title":"Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk","volume":"17","author":"Behera","year":"2024","journal-title":"BMC Med Genom"},{"key":"10.1016\/j.athplu.2026.100569_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-Lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.athplu.2026.100569_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014581","article-title":"Single-Nucleotide polymorphisms in LPA explain Most of the ancestry-specific variation in lp(a) levels in African Americans","volume":"6","author":"Deo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2026.100569_bib42","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0022-2275(20)41895-4","article-title":"Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation","volume":"32","author":"Helmhold","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jacasi.2025.04.012","article-title":"Cardiovascular implications of Lipoprotein(a) and its genetic variants","volume":"5","author":"El-Menyar","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.athplu.2026.100569_bib45","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to Race\/Ethnicity, Apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas heart Study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100569_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ihj.2022.08.003","article-title":"Premature coronary artery disease, risk factors, clinical presentation, angiography and interventions: hospital based registry","volume":"74","author":"Sharma","year":"2022","journal-title":"Indian Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0003319719849737","article-title":"Premature myocardial infarction in the Middle East and North Africa: rationale for the Gulf PREVENT Study","volume":"71","author":"Dugani","year":"2020","journal-title":"Angiology"},{"key":"10.1016\/j.athplu.2026.100569_bib49","article-title":"Coronary artery disease in Africa and the Middle East","volume":"65","author":"Almahmeed","year":"2012","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.athplu.2026.100569_bib50","doi-asserted-by":"crossref","first-page":"zwaf374","DOI":"10.1093\/eurjpc\/zwaf374","article-title":"Lipoprotein(a) testing and levels among patients with atherosclerotic cardiovascular disease: a large single-centre experience from the United Arab Emirates","author":"Manla","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib52","first-page":"65","article-title":"Comparison of cardiac risk scores among the East Mediterranean and South Asian population","volume":"32","author":"Alenazi","year":"2022","journal-title":"Ethiop J Health Sci"},{"key":"10.1016\/j.athplu.2026.100569_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040680","article-title":"External validation and clinical usefulness of three commonly used cardiovascular risk prediction scores in an Emirati population: a retrospective longitudinal cohort study","volume":"10","author":"Al-Shamsi","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.athplu.2026.100569_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-021-00940-5","article-title":"Lipoprotein (a): recent Updates on a Unique Lipoprotein","volume":"23","author":"Saeed","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.athplu.2026.100569_bib55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring Lipoprotein(a) during Cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: lower is better for longer\u2014even at low risk","volume":"18","author":"Penson","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.athplu.2026.100569_bib57","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1194\/jlr.C085639","article-title":"In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes1","volume":"59","author":"Tsimikas","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib58","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and Risk of Type 2 Diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2026.100569_bib59","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4239\/wjd.v12.i9.1401","article-title":"Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action","volume":"12","author":"El-Kebbi","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.athplu.2026.100569_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.athplu.2026.100569_bib61","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","article-title":"Kringle IV type 2, not low Lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with Lipoprotein(a) concentrations or with Kringle IV type 2 repeats","volume":"63","author":"Tolbus","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2026.100569_bib62","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-019-4909-y","article-title":"Type 2 diabetes: a multifaceted disease","volume":"62","author":"Pearson","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.athplu.2026.100569_bib63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1573399813666170920152913","article-title":"Epidemiology of diabetes mellitus in the United Arab Emirates","volume":"14","author":"Razzak","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.athplu.2026.100569_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000506508","article-title":"Emirates Diabetes Society Consensus Guidelines for the management of type 2 diabetes mellitus \u2013 2020","volume":"26","author":"Alawadi","year":"2020","journal-title":"Dubai Diabetes Endocrinol J"},{"key":"10.1016\/j.athplu.2026.100569_bib65","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/jcm13041102","article-title":"Genetic susceptibility to arrhythmia phenotypes in a Middle Eastern cohort of 14,259 whole-genome sequenced individuals","volume":"13","author":"Qafoud","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2026.100569_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50876-9","article-title":"Introducing the first whole genomes of nationals from the United Arab Emirates","volume":"9","author":"AlSafar","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100569_bib67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2026.100569_bib68","doi-asserted-by":"crossref","first-page":"oeaf069","DOI":"10.1093\/ehjopen\/oeaf069","article-title":"Glycolysis hijacked: a novel pathogenic role of lipoprotein(a) in valve disease","volume":"5","author":"Weiss","year":"2025","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.athplu.2026.100569_bib69","article-title":"Lipoprotein(a): an important piece of the ASCVD risk factor puzzle across diverse populations","volume":"38","author":"Ciffone","year":"2024","journal-title":"Am Heart J Plus Cardiol Res Pract"},{"key":"10.1016\/j.athplu.2026.100569_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1439013","article-title":"Trends and findings of lipoprotein(a) testing and associated cardiovascular disease profiles: a large single-center study from the Middle East-Gulf region","volume":"11","author":"Manla","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.athplu.2026.100569_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a) \u2013 seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib73","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"Unmet needs in understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group recommendations to reduce risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib76","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib77","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib78","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required Lipoprotein(a)-Lowering therapeutic effect size for reduction in coronary heart disease outcomes","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib79","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib80","first-page":"ehaf190","article-title":"Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"2025","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.maturitas.2022.08.001","article-title":"Dyslipidemia in midlife women: approach and considerations during the menopausal transition","volume":"166","author":"Torosyan","year":"2022","journal-title":"Maturitas"},{"key":"10.1016\/j.athplu.2026.100569_bib82","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/nu15030693","article-title":"High-Risk Lipoprotein(a) levels in Saudi women and its relationship to menopause and adiposity","volume":"15","author":"Aljawini","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.athplu.2026.100569_bib83","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower Lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2026.100569_bib86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib87","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy and risk of future cardiovascular events","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib88","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211013917","article-title":"Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use","volume":"12","author":"Prabakaran","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.athplu.2026.100569_bib90","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2026.100569_bib91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11789-019-00101-8","article-title":"Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?","volume":"14","author":"Nave","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.athplu.2026.100569_bib92","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that Lipoprotein(a) Associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100569_bib93","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.thromres.2010.06.007","article-title":"Serum Lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE","volume":"126","author":"Rodger","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.athplu.2026.100569_bib94","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of Lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib96","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.athplu.2026.100569_bib97","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MOL.0000000000000838","article-title":"Considerations for routinely testing for high lipoprotein(a)","volume":"34","author":"Nurmohamed","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hlc.2022.11.015","article-title":"Australian atherosclerosis Society position statement on Lipoprotein(a): clinical and implementation recommendations","volume":"32","author":"Ward","year":"2023","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.athplu.2026.100569_bib99","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib100","doi-asserted-by":"crossref","first-page":"oeae031","DOI":"10.1093\/ehjopen\/oeae031","article-title":"Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"4","author":"Tian","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.athplu.2026.100569_bib101","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","article-title":"Finding very high lipoprotein(a): the need for routine assessment","volume":"29","author":"Nurmohamed","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.athplu.2026.100569_bib103","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib104","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with Lipoprotein(a): prospective 15-Year outcomes in the bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib105","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme Lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib106","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"Hoek","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.athplu.2026.100569_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure Lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2026.100569_bib109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2021.11.004","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)","volume":"349","author":"Chakraborty","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100945","article-title":"Rethinking cardiovascular risk: the emerging role of lipoprotein(a) screening","volume":"21","author":"Clair","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib111","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MOL.0000000000000951","article-title":"Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder","volume":"35","author":"Annink","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib112","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce Lipoprotein(a)-Mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib113","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, Rosuvastatin Therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib114","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034493","article-title":"Association of Lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the mass general Brigham Lp(a) registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2026.100569_bib116","doi-asserted-by":"crossref","first-page":"L53","DOI":"10.1093\/eurheartj\/suaa135","article-title":"Lipoprotein(a) and PCSK9 inhibition: clinical evidence","volume":"22","author":"Ruscica","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib117","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with Proprotein Convertase Subtilisin\/Kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.athplu.2026.100569_bib118","article-title":"Impact of pcsk-9 inhibitors on lipoprotein(a): a meta-analysis and meta-regression of 47 randomized controlled trials","volume":"83","author":"Rivera","year":"2024","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.athplu.2026.100569_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70174","article-title":"PCSK9 inhibitors: the evolving future","volume":"7","author":"Jeswani","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.athplu.2026.100569_bib120","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib121","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.mayocp.2024.03.025","article-title":"Effects of inclisiran in patients with atherosclerotic cardiovascular disease","volume":"99","author":"Wright","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.athplu.2026.100569_bib122","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12872-022-02932-y","article-title":"Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.athplu.2026.100569_bib123","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"De Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib124","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.athplu.2026.100569_bib125","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib126","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1902\/jop.2008.080249","article-title":"Inflammation, c\u2010reactive protein, and atherothrombosis","volume":"79","author":"Ridker","year":"2008","journal-title":"J Periodontol"},{"key":"10.1016\/j.athplu.2026.100569_bib127","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12889-021-10760-6","article-title":"Validation of the Framingham hypertension risk score in a middle eastern population: tehran lipid and glucose study (TLGS)","volume":"21","author":"Koohi","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.athplu.2026.100569_bib128","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/j.jacc.2021.04.052","article-title":"Systematic coronary risk evaluation (SCORE)","volume":"77","author":"Graham","year":"2021","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.athplu.2026.100569_bib129","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12872-024-04390-0","article-title":"Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the global burden of disease study 1990\u20132021","volume":"24","author":"Soleimani","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.athplu.2026.100569_bib130","unstructured":"Oman Study of Lipoprotein.(a) levels in acute coronary syndrome (Oman SAVECARE). Sultan Qaboos Univ House Expert n.d. https:\/\/squ.elsevierpure.com\/en\/projects\/oman-study-of-lipoproteina-levels-in-acute-coronary-syndrome-oman-2 (accessed May 25, 2025)."},{"key":"10.1016\/j.athplu.2026.100569_bib131","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035930","article-title":"Disease risk Score derivation and validation in Abu Dhabi, United Arab Emirates: a retrospective cohort Study","author":"AlKetbi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2026.100569_bib132","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","author":"Hippisley-Cox","year":"2017","journal-title":"Br Med J"},{"key":"10.1016\/j.athplu.2026.100569_bib133","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/1570161113666151026115921","article-title":"Control of Risk factors for cardiovascular disease among multinational patient population in the arabian Gulf","volume":"14","author":"Al-Zakwani","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.athplu.2026.100569_bib134","doi-asserted-by":"crossref","unstructured":"Tash AA, Al-Bawardy RF. Cardiovascular disease in Saudi Arabia: facts and the way forward. J Saudi Heart Assoc n.d.;35:148\u2013162. https:\/\/doi.org\/10.37616\/2212-5043.1336.","DOI":"10.37616\/2212-5043.1336"},{"key":"10.1016\/j.athplu.2026.100569_bib135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib136","unstructured":"Lp (a) Clinical Guidance n.d. https:\/\/www.lpaclinicalguidance.com\/(accessed April 8, 2025)."},{"key":"10.1016\/j.athplu.2026.100569_bib137","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.124.004631","article-title":"Lipoprotein(a) atherosclerotic cardiovascular disease risk Score development and prediction in primary prevention from real-world data","volume":"18","author":"Fan","year":"2025","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.athplu.2026.100569_bib138","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in Lipoprotein(a) levels among patients with coronary heart disease","volume":"85","author":"Barkas","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100686","article-title":"Testing practices and clinical management of lipoprotein(a) levels: a 5-year retrospective analysis from the Johns Hopkins Hospital","volume":"19","author":"Eidensohn","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health System in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2026.100569_bib141","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib142","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for Lipoprotein(a)-Lowering therapies","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib143","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of Pelacarsen on Lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100886","article-title":"Lipoprotein (a) testing patterns among subjects with a measured lipid panel: the Mayo Clinic experience","volume":"20","author":"Manzato","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib146","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of Lipoprotein(a) and low-density lipoprotein cholesterol\u2013mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib147","doi-asserted-by":"crossref","DOI":"10.1177\/17539447241249650","article-title":"Use of coronary artery calcium score and coronary CT angiography to guide cardiovascular prevention and treatment","volume":"18","author":"Lima","year":"2024","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2026.100569_bib148","article-title":"The role of cardiac computed tomography angiography in risk stratification for coronary artery disease","volume":"3","author":"Rosendael","year":"2024","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"10.1016\/j.athplu.2026.100569_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2022.100107","article-title":"Relationship between lipoprotein (a) and subclinical carotid atherosclerosis in asymptomatic individuals","volume":"77","author":"Fran\u00e7a","year":"2022","journal-title":"Clinics"},{"key":"10.1016\/j.athplu.2026.100569_bib150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent Association of Lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib151","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jep.12337","article-title":"The development, implementation and evaluation of clinical practice guidelines in G ulf C ooperation C ouncil (GCC) countries: a systematic review of literature","volume":"21","author":"Koornneef","year":"2015","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.athplu.2026.100569_bib152","unstructured":"An update on Lipoprotein(a): the latest on Testing, Treatment, and Guideline recommendations. Am Coll Cardiol n.d. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2023\/09\/19\/10\/54\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2023%2f09%2f19%2f10%2f54%2fan-update-on-lipoprotein-a (accessed April 9, 2025)."},{"key":"10.1016\/j.athplu.2026.100569_bib153","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.3390\/jcm12237432","article-title":"Evolution of more aggressive LDL-Cholesterol targets and therapies for cardiovascular disease prevention","volume":"12","author":"Jones","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2026.100569_bib154","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib155","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after Acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib156","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.jacl.2024.04.134","article-title":"Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation","volume":"18","author":"Schumann","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib157","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib158","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","article-title":"Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Dicembrini","year":"2019","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.athplu.2026.100569_bib159","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2026.100569_bib161","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2026.100569_bib162","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib163","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib164","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density Lipoprotein cholesterol and Lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.athplu.2026.100569_bib165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib166","series-title":"A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)","year":"2025"},{"key":"10.1016\/j.athplu.2026.100569_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.03.036","article-title":"Oral PCSK9 inhibitor enlicitide versus oral Non-statin therapies: a phase 3 randomized clinical trial","author":"Catapano","year":"2026","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.athplu.2026.100569_bib168","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib169","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.athplu.2026.100569_bib170","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.100569_bib171","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.athplu.2026.100569_bib172","article-title":"Lp(a) or Lipoprotein (a): a comprehensive review","author":"Moazzeni","year":"2024","journal-title":"Hear Syd"},{"key":"10.1016\/j.athplu.2026.100569_bib173","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib174","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100569_bib175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/PPA.S478623","article-title":"Living with elevated Lipoprotein(a) levels: the experiences of patients and caregivers","volume":"19","author":"Steinhagen-Thiessen","year":"2025","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.athplu.2026.100569_bib176","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MOL.0000000000000950","article-title":"Strategies for management of patients with elevated lipoprotein(a)","volume":"35","author":"Ellberg","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2026.100569_bib177","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100569_bib178","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100569_bib179","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s40001-023-01155-x","article-title":"Association of statin use and increase in lipoprotein(a): a real-world database research","volume":"28","author":"Feng","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.athplu.2026.100569_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100626","article-title":"Understanding the use of lipoprotein (a) in the primary care office for primary prevention: a fellow's voice","volume":"16","author":"Vergara Sanchez","year":"2023","journal-title":"Am J Prev Cardiol"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:50:31Z","timestamp":1790265031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089526000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":179,"alternative-id":["S2667089526000234"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100569","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100569"}}